Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Halfvarson

Showing results (171-180 of 244) with videos related to

Pageof 25
Sort By:
Journal of Crohn'S & Colitis|January 25, 2023
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel DiseaseArchana Shubhakar, Bas C Jansen, Alex T Adams, et al.
Inflammatory Bowel Diseases|October 26, 2018
Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk LociKimi Drobin, Ghazaleh Assadi, Mun-Gwan Hong, et al.
Gut|June 4, 2011
Association of TNFSF15 polymorphism with irritable bowel syndromeMarco Zucchelli, Michael Camilleri, Anna Nixon Andreasson, et al.
Therapeutic Advances in Gastroenterology|July 19, 2021
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyCarl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, et al.
JHEP Reports : Innovation in Hepatology|February 24, 2026
Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulationsMartin Cornillet, Aiva Lundberg Båve, Dan Sun, et al.
Gut Microbes|October 6, 2025
First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort studyPhilipp Rausch, Ilka Ratjen, Lukas Tittmann, et al.
Gut|September 18, 2013
Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndromeMira M Wouters, Diether Lambrechts, Michael Knapp, et al.
Drugs|February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Clinical and Experimental Gastroenterology|June 10, 2025
Microbial Patterns in Newly Diagnosed Inflammatory Bowel Disease Revealed by Presence and Transcriptional Activity - Relationship to Diagnosis and OutcomeSimen Svendsen Vatn, Simen Hyll Hansen, Tone Møller Tannæs, et al.
Drugs|June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Pageof 25

Showing results (171-180 of 244) with videos related to

Sort By:
Pageof 25
Journal of Crohn'S & Colitis|January 25, 2023
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel DiseaseArchana Shubhakar, Bas C Jansen, Alex T Adams, et al.
Inflammatory Bowel Diseases|October 26, 2018
Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk LociKimi Drobin, Ghazaleh Assadi, Mun-Gwan Hong, et al.
Gut|June 4, 2011
Association of TNFSF15 polymorphism with irritable bowel syndromeMarco Zucchelli, Michael Camilleri, Anna Nixon Andreasson, et al.
Therapeutic Advances in Gastroenterology|July 19, 2021
Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH studyCarl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, et al.
JHEP Reports : Innovation in Hepatology|February 24, 2026
Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulationsMartin Cornillet, Aiva Lundberg Båve, Dan Sun, et al.
Gut Microbes|October 6, 2025
First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort studyPhilipp Rausch, Ilka Ratjen, Lukas Tittmann, et al.
Gut|September 18, 2013
Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndromeMira M Wouters, Diether Lambrechts, Michael Knapp, et al.
Drugs|February 1, 2020
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Clinical and Experimental Gastroenterology|June 10, 2025
Microbial Patterns in Newly Diagnosed Inflammatory Bowel Disease Revealed by Presence and Transcriptional Activity - Relationship to Diagnosis and OutcomeSimen Svendsen Vatn, Simen Hyll Hansen, Tone Møller Tannæs, et al.
Drugs|June 4, 2020
Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory DiseasesHoUng Kim, Rieke Alten, Luisa Avedano, et al.
Pageof 25